111 related articles for article (PubMed ID: 26573420)
1. Can FCR be curative in CLL?
Killock D
Nat Rev Clin Oncol; 2015 Dec; 12(12):684. PubMed ID: 26573420
[No Abstract] [Full Text] [Related]
2. FCR holds up to the test of time: CLL8 follow-up.
Woyach JA
Blood; 2016 Jan; 127(2):172-3. PubMed ID: 26769769
[No Abstract] [Full Text] [Related]
3. Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.
Thompson PA; Tam CS
Oncology (Williston Park); 2018 Jun; 32(6):291-2, 294-6. PubMed ID: 29940059
[No Abstract] [Full Text] [Related]
4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Fischer K; Bahlo J; Fink AM; Goede V; Herling CD; Cramer P; Langerbeins P; von Tresckow J; Engelke A; Maurer C; Kovacs G; Herling M; Tausch E; Kreuzer KA; Eichhorst B; Böttcher S; Seymour JF; Ghia P; Marlton P; Kneba M; Wendtner CM; Döhner H; Stilgenbauer S; Hallek M
Blood; 2016 Jan; 127(2):208-15. PubMed ID: 26486789
[TBL] [Abstract][Full Text] [Related]
5. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J; Garcia-Vela JA; Gómez S; Fernández-Cuevas B; Nova-Gurumeta S; Pérez-Sanz N; Alcoceba M; González M; Anguita E; López-Jiménez J; González-Barca E; Yáñez L; Pérez-Persona E; de la Serna J; Fernández-Zarzoso M; Deben G; Peñalver FJ; Fernández MC; de Oteyza JP; Andreu MÁ; Ruíz-Guinaldo MÁ; Paz-Arias R; García-Malo MD; Recasens V; Collado R; Córdoba R; Navarro-Matilla B; Sánchez-Beato M; García-Marco JA
PLoS One; 2021; 16(9):e0257353. PubMed ID: 34506616
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
7. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
[TBL] [Abstract][Full Text] [Related]
8. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
Shah N; Tam C; Seymour JF; Rule S
Leuk Lymphoma; 2015 Jun; 56(6):1599-610. PubMed ID: 25213181
[TBL] [Abstract][Full Text] [Related]
9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
10. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
[TBL] [Abstract][Full Text] [Related]
11. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Wierda WG
Clin Adv Hematol Oncol; 2019 Apr; 17(4):214-216. PubMed ID: 31188811
[No Abstract] [Full Text] [Related]
12. [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].
Han HJ; Lu YW; Xia RX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):25-9. PubMed ID: 26913388
[TBL] [Abstract][Full Text] [Related]
13. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
Kutsch N; Busch R; Bahlo J; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Wendtner CM; Maria Fink A; Fischer K; Hallek M; Eichhorst B
Leuk Lymphoma; 2017 Feb; 58(2):399-407. PubMed ID: 27357445
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
15. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
Ysebaert L; Larcher M; Compaci G; Oberic L; Sahnes L; Banos A; Araujo C; Sommet A; Laurent G; Despas F
Ann Hematol; 2019 Apr; 98(4):931-939. PubMed ID: 30778715
[TBL] [Abstract][Full Text] [Related]
16. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
18. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
19. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
